Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CASR | P41180 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL343227 | 1.00 | TSHR (0.46) | TSHRALDH1A1L3MBTL1ESR2MAPK1 | |
| SCHEMBL27845866 | 0.84 | ESR2 (0.46) | TSHRALDH1A1L3MBTL1ESR2MAPK1 | |
| SCHEMBL11604414 | 0.84 | TSHR (0.46) | TSHRALDH1A1L3MBTL1ESR2HPGD | |
| SCHEMBL28046789 | 0.83 | TSHR (0.43) | TSHRALDH1A1L3MBTL1ESR2MAPK1 | |
| SCHEMBL28715842 | 0.82 | TSHR (0.44) | TSHRALDH1A1L3MBTL1ESR2HPGD | |
| SCHEMBL29835035 | 0.82 | TSHR (0.50) | TSHRALDH1A1L3MBTL1MAPK1SMN1; SMN2 | |
| SCHEMBL254017 | 0.82 | TSHR (0.50) | TSHRALDH1A1L3MBTL1MAPK1SMN1; SMN2 | |
| SCHEMBL25409749 | 0.80 | TSHR (0.41) | TSHRALDH1A1L3MBTL1ESR2MAPK1 | |
| SCHEMBL10470446 | 0.80 | L3MBTL1 (0.44) | TSHRALDH1A1L3MBTL1ESR2MAPK1 | |
| SCHEMBL84270 | 0.80 | TSHR (0.36) | TSHRALDH1A1L3MBTL1ESR2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110835361-A | Sialic acid glycosyl donor and preparation method and application thereof | 山东大学 | 2020-02-25 | — | — | CN | claimed |
| EP-4709725-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024233642-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| CN-114956933-A | Marker containing isotope oxygen atom and preparation method and application thereof | 清华大学 | 2022-08-30 | — | — | CN | disclosed |
| CN-111517902-B | Aerobic oxidation system containing sulfinic acid, sulfonic acid or derivatives thereof and photo-oxidation promoting method thereof | 清华大学 | 2022-06-14 | — | — | CN | disclosed |
| EP-3801896-A1 | RAPIDLY RELEASED BIOORTHOGONAL CAGING GROUPS | University of Utah Research Foundation (US) | 2021-04-14 | — | — | EP | disclosed |
| CN-111517902-A | Aerobic oxidation system containing sulfinic acid, sulfonic acid or derivatives thereof and photo-oxidation promoting method thereof | 清华大学 | 2020-08-11 | — | — | CN | disclosed |
| CN-110835361-A | Sialic acid glycosyl donor and preparation method and application thereof | 山东大学 | 2020-02-25 | — | — | CN | disclosed |
| CN-104024253-A | Heterocyclic amines as PI3K inhibitors | INCYTE CORP | 2014-09-03 | — | — | CN | disclosed |
| CN-103874493-A | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME | 2014-06-18 | — | — | CN | disclosed |
| WO-2010112461-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2010-10-07 | — | — | WO | disclosed |
| EP-1727788-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2010-07-28 | — | — | EP | disclosed |
| US-7381750-B2 | Amino-phenoxymethyl-benzamide opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-20070287751-A1 | Opioid Receptor Antagonists | ELI LILLY AND COMPANY | 2007-12-13 | — | — | US | disclosed |
| EP-1727788-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-12-06 | — | — | EP | disclosed |
| CN-1274839-C | Process for the preparation of enantiomerically enriched esters and alcohols | DSM NV (NL) | 2006-09-13 | — | — | CN | disclosed |
| WO-2005090286-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-29 | — | — | WO | disclosed |
| CN-1430677-A | Process for the preparation of enantiomerically enriched esters and alcohols | DSM NV (NL) | 2003-07-16 | — | — | CN | disclosed |
| US-5698560-A | TREATMENT OF CARDIOVASCULAR DISORDERS; ANTICOAGULANTS; CARDIOTONIC AGENTS; HYPOTENSIVE AGENTS; ARTERIOSCLEROSIS; CYCLIC GMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-12-16 | — | — | US | disclosed |
| EP-0758653-A1 | IMIDAZOQUINAZOLINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287751-A1 | Opioid Receptor Antagonists | OPRK1, OPRM1, OPRD1 | TSHR 284/4885ALDH1A1 2190/4885L3MBTL1 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.